Massachusetts’ life sciences sector, long one of the state’s signature industries, is going through another rough patch. Fourteen companies announced layoffs in the first quarter of 2026, cutting a combined 745 jobs across the state’s biotech and pharma cluster.
A pause, then a reversal
Layoff activity in the sector had been easing toward the end of 2025, giving the industry some room to hope the worst had passed. That reprieve didn’t last. Tracking from the Boston Business Journal shows the pace of cuts picking back up in the first months of 2026, with job losses spread across more than a dozen companies rather than concentrated in one or two large employers.
Advertisement
Part of a broader strain on the state’s core industries
The renewed biotech layoffs are landing at the same time other pillars of the Massachusetts economy — higher education and health care among them — are also under financial pressure. Venture capital’s share of funding flowing to the state’s life sciences companies has slipped, and the number of companies receiving funding has declined as well, making it harder for early-stage biotechs to bridge the gap after a round of cuts.
Why it matters beyond biotech
Life sciences has been one of the largest sources of high-wage employment growth in Greater Boston over the past two decades, and hiring in the sector has a outsized ripple effect on lab real estate, specialized construction, and professional services. Continued layoffs, even at a moderate pace, are one reason the state’s overall job growth — positive on paper — still feels uneven to workers in Cambridge, Lexington, and the other lab-heavy suburbs that built their local economies around the industry’s expansion.
What to watch
Boston Made’s Economy desk will track quarterly layoff totals as they’re reported, along with lab vacancy rates and venture funding data, to see whether this is a short-lived correction or the start of a longer contraction.
Background
Massachusetts has one of the largest life sciences clusters in the world, concentrated in Cambridge, Boston and suburban communities along major highways. The industry includes biotechnology companies developing new medicines, larger pharmaceutical firms, medical device makers and the contract research and manufacturing companies that support them. Its growth over recent decades drew on the region’s universities, hospitals and a deep pool of investors.
Advertisement
The industry is also known for volatility. Many biotech companies are not yet profitable and depend on raising money to fund research. Clinical trial results, regulatory decisions and investor sentiment can quickly change a company’s prospects. When a trial fails or funding becomes harder to secure, companies often cut staff to conserve cash, sometimes shutting down programs or focusing on a smaller number of projects.
Why layoffs happen in cycles
Layoffs in biotech tend to cluster when funding conditions tighten. During periods when investors are eager to back new companies, many startups form and hire quickly. When investors become more cautious, companies that cannot raise new money may reduce staff or close. Larger companies also restructure periodically, merging departments or exiting research areas as their strategies change.
- Pipeline changes: a failed trial or deprioritized program can lead to cuts.
- Funding gaps: companies extend runway by reducing headcount.
- Mergers: combined companies often consolidate overlapping roles.
- Strategic shifts: firms may exit certain research areas entirely.
What it means for Boston-area readers
For workers affected by layoffs, the federal Worker Adjustment and Retraining Notification Act, known as the WARN Act, generally requires larger employers to provide advance notice of certain mass layoffs and plant closings. State career centers, professional associations and university networks can also help with job searches and retraining. Unemployment insurance is available to eligible workers through the state.
For the broader region, life sciences employment supports a wide range of other businesses: lab equipment suppliers, construction trades, real estate, restaurants and services. Changes in the sector can ripple outward, which is one reason the data is watched closely. Communities with many lab buildings may also see effects on commercial property values and local tax revenue when space sits empty for long periods, which connects industry trends to municipal budgets and services.
- Laid-off workers can check eligibility for unemployment benefits promptly.
- Career centers and industry groups often host job fairs and networking events.
- Skills in research, regulatory affairs, quality and data analysis can transfer across companies and sectors.
Key terms
- Life sciences cluster: a regional concentration of biotech, pharma and related companies.
- Clinical trial: a research study that tests a treatment in people.
- Pipeline: the set of drug candidates a company is developing.
- WARN Act: a federal law requiring advance notice of certain large layoffs.
- Runway: how long a company’s cash will last at its current spending rate.
- Restructuring: reorganizing a company’s operations, often including job cuts.
What to watch
- Quarterly layoff totals as reported by the Boston Business Journal and other trackers.
- Venture funding trends for Massachusetts life sciences companies.
- Lab vacancy rates in Cambridge, Boston and surrounding suburbs.
- Major clinical trial readouts and regulatory decisions for local companies.
- Hiring announcements and expansions that may offset cuts.
Looking at layoffs alongside hiring, funding and real estate data gives a more complete view than any single measure, since the sector can contract in some areas while growing in others. Announcements from individual companies, state economic development offices and industry groups each add part of the picture.
Quick check: How many life sciences jobs were cut across Massachusetts companies in the first quarter of 2026, according to the article?
- 145
- 745
- 1,745
Show answer
B. Fourteen companies announced layoffs totaling 745 jobs in the first quarter.